Physician profile
Adedotun Ogunsua
NPI 1922448661
$14,090.95
in general payments reported to CMS, 2019-2025
34 companies · $2,168 in 2025
The $2,168 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $751 · 2020: $218 · 2021: $571 · 2022: $7,267 · 2023: $2,031 · 2024: $1,087 · 2025: $2,168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,062 · Food and Beverage: $2,223.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,061.96 |
| Food and Beverage | $2,222.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Penumbra, INC. | $4,060.04 | 2022-2023 | Indigo System |
| Terumo Medical Corporation | $3,548.02 | 2022 | |
| Teleflex LLC | $1,582.92 | 2022-2025 | Guideliner, Supercross |
| Boston Scientific Corporation | $1,168.90 | 2020-2025 | Avvigo Guidance System, Stingray |
| Abiomed | $444.43 | 2019-2025 | |
| Cardiovascular Systems INC. | $402.74 | 2021-2022 | |
| Medtronic, INC. | $362.37 | 2022-2025 | Symplicity G3, Onyx Frontier |
| E.R. Squibb & Sons, L.L.C. | $266.78 | 2020-2023 | Eliquis, Camzyos |
| Inari Medical, INC. | $238.32 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $214.68 | 2021-2023 | Uptravi, Opsumit |
| Novo Nordisk INC | $176.24 | 2024-2025 | Wegovy |
| Philips North America LLC | $168.05 | 2019 | |
| Merck Sharp & Dohme LLC | $166.60 | 2021-2023 | Verquvo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $163.30 | 2020-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $141.73 | 2021-2023 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $140.24 | 2019 | |
| Janssen Pharmaceuticals, INC | $100.20 | 2021-2022 | |
| Cardinal Health 200 LLC | $91.80 | 2019 | |
| Shockwave Medical, INC | $84.10 | 2022-2025 | Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave C2+ Coronary |
| Heartflow, INC. | $71.61 | 2021-2024 | |
| Cardiva Medical, INC. | $58.47 | 2025 | Cardiva Vascade 6/7f Vcs |
| Amgen INC. | $56.43 | 2020-2022 | |
| Atricure, INC. | $56.02 | 2025 | Epi-Sense Guided Coagulation System With Visitrax |
| Cook Medical LLC | $52.63 | 2025 | Zilver Ptx |
| Pfizer INC. | $49.78 | 2021-2023 | |
| Astrazeneca Pharmaceuticals Lp | $45.39 | 2021-2023 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.55 | 2021-2025 | Jardiance |
| Chiesi USA, INC. | $32.44 | 2020 | |
| Alnylam Pharmaceuticals INC. | $21.88 | 2025 | Onpattro |
| Esperion Therapeutics, INC. | $19.63 | 2021 | |
| Ge Healthcare | $18.81 | 2021 | |
| Lemaitre Vascular, INC. | $18.42 | 2021 | |
| Cordis US Corp. | $16.33 | 2023 | Zephyr |
| Genzyme Corporation | $12.10 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adedotun Ogunsua listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.